| Verifiedfields: | changed |
| Verifiedrevid: | 464213376 |
| Width: | 181 |
| Tradename: | Pravachol, Selektine, others |
| Dailymedid: | Pravastatin |
| Pregnancy Au: | D |
| Routes Of Administration: | By mouth |
| Atc Prefix: | C10 |
| Atc Suffix: | AA03 |
| Legal Au: | S4 |
| Legal Ca: | Rx-only |
| Legal Uk: | POM |
| Legal Us: | Rx-only |
| Legal Eu: | Rx-only |
| Legal Eu Comment: | [1] |
| Bioavailability: | 18%[2] |
| Protein Bound: | 50% |
| Metabolism: | Liver (minimal) |
| Elimination Half-Life: | 1-3 hours |
| Index2 Label: | as salt |
| Cas Number: | 81093-37-0 |
| Pubchem: | 54687 |
| Iuphar Ligand: | 2953 |
| Drugbank: | DB00175 |
| Chemspiderid: | 49398 |
| Unii: | KXO2KT9N0G |
| Kegg: | D08410 |
| Kegg2: | D00893 |
| Chebi: | 63618 |
| Chembl: | 1144 |
| Iupac Name: | (3R,5R)-3,5-dihydroxy-7-((1R,2S,6S,8R,8aR)-6-hydroxy-2-methyl-8--1,2,6,7,8,8a-hexahydronaphthalen-1-yl)-heptanoic acid |
| C: | 23 |
| H: | 36 |
| O: | 7 |
| Smiles: | O=C(O)C[C@H](O)C[C@H](O)CC[C@H]2[C@H](/C=C\C1=C\[C@@H](O)C[C@H](OC(=O)[C@@H](C)CC)[C@@H]12)C |
| Stdinchi: | 1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1 |
| Stdinchikey: | TUZYXOIXSAXUGO-PZAWKZKUSA-N |
Pravastatin, sold under the brand name Pravachol among others, is a statin medication, used for preventing cardiovascular disease in those at high risk and treating abnormal lipids. It is suggested to be used together with diet changes, exercise, and weight loss. It is taken by mouth.[3]
Common side effects include joint pain, diarrhea, nausea, headaches, and muscle pains.[3] Serious side effects may include rhabdomyolysis, liver problems, and diabetes.[3] Use during pregnancy may harm the fetus.[3] Like all statins, pravastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver that plays a role in producing cholesterol.[3]
Pravastatin was patented in 1980 and approved for medical use in 1989.[4] It is on the World Health Organization's List of Essential Medicines.[5] It is available as a generic medication.[3] In 2021, it was the 39th most commonly prescribed medication in the United States, with more than 15million prescriptions.[6] [7]
Pravastatin is primarily used for the treatment of dyslipidemia and the prevention of cardiovascular disease.[8] It is recommended to be used only after other measures, such as diet, exercise, and weight reduction, have not improved cholesterol levels.
Pravastatin has been shown to have a similar effectiveness at lowering low-density lipoprotein cholesterol as other statin medications such as fluvastatin but may low level evidence indicates that pravastatin may not be as effective as some other statin medications that are available.[9] The beneficial effect of pravastatin is dependent on the dose and the potential for side effects or unwanted effects from this medication are not clear from clinical trials.
Pravastatin has undergone over 112,000 patient-years of double-blind, randomized trials using the 40 mg, once-daily dose and placebos. These trials indicate pravastatin is well tolerated and displays few noncardiovascular abnormalities in patients.[10] However, side effects may occur. A doctor should be consulted if symptoms such as heartburn or headache are severe and do not go away.
These uncommon side effects should be promptly reported to the prescribing doctor or an emergency medical service:
These symptoms should be reported to the prescribing doctor if they persist or increase in severity:
Contraindications, conditions that warrant withholding treatment with pravastatin, include pregnancy and breastfeeding.[11] Taking pravastatin while pregnant could lead to birth defects. While the amount of pravastatin ingested by an infant from breastfeeding is low, patients breastfeeding should not take pravastatin due to potential effects on the infant's lipid metabolism.[12]
Medications that should not be taken with pravastatin include, but are not limited to:[8] [11]
Pravastatin is cleared by the kidneys, giving it a distinct advantage over other statins when a potential for drug interactions using the hepatic pathway exists.
The combination of fenofibrate with pravastatin is approved for use in the European Union.[13]
Pravastatin acts as a lipoprotein-lowering drug through two pathways. In the major pathway, pravastatin inhibits the function of hydroxymethylglutaryl-CoA (HMG-CoA) reductase. As a reversible competitive inhibitor, pravastatin sterically hinders the action of HMG-CoA reductase by occupying the active site of the enzyme. Taking place primarily in the liver, this enzyme is responsible for the conversion of HMG-CoA to mevalonate in the rate-limiting step of the biosynthetic pathway for cholesterol. Pravastatin also inhibits the synthesis of very-low-density lipoproteins, which are the precursor to low-density lipoproteins (LDL). These reductions increase the number of cellular LDL receptors, thus LDL uptake increases, removing it from the bloodstream.[14] Overall, the result is a reduction in circulating cholesterol and LDL. A minor reduction in triglycerides and an increase in high-density lipoproteins (HDL) are common.
Oral bioavailability of pravastatin ranges from 17-34% with peak plasma concentration achieved 1-1.5 hours after administration. Absorption of drug is modestly decreased when taken with food however this does not reduce the clinical lipid-lowering effect.[15]
The 3α-hydroxyisomeric metabolite of pravastatin is also an active HMG-CoA reductase inhibitor with approximately 2.5-10% the potency of the parent compound. Pravastatin has a plasma half-life of 1.8 hours whereas this active metabolite has a half-life up to 77 hours.
Initially known as CS-514, pravastatin is a derivative of ML236B (compactin), which was identified in a fungus called Penicillium citrinum in the 1970s by researchers of the Sankyo Pharma Inc.[16] It is being marketed outside Japan by the pharmaceutical company Bristol-Myers Squibb. In 2005, Pravachol was the 22nd-highest selling brand-name drug in the United States, with sales totaling $1.3 billion.[17]
The Food and Drug Administration (FDA) approved generic pravastatin for use in the United States on 24 April 2006. Generic pravastatin sodium tablets were manufactured by Biocon Ltd, India and TEVA Pharmaceuticals in Kfar Sava, Israel.